Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors

Objectives: To describe symptoms, delay in presentation and reasons for non-presentation among women diagnosed with benign, low malignant potential and malignant ovarian tumors.

Methods: Study participants included 457 women who underwent surgery for an ovarian tumor in Queensland, Australia, between July 1999 and February 2002 (244 with invasive cancer, 62 with low malignant potential tumors, and 151 with benign ovarian tumors). Women were contacted a minimum of three months post-diagnosis. Information concerning symptoms and presentation history was obtained via interview.

Results: Overall, only 8% of the women were asymptomatic at the time of their diagnosis. Women with invasive cancer reported a greater number of symptoms (3.1 and 3.6 for Stages I-II and III-IV, respectively) than women with benign or low malignant potential tumors (2.8 and 2.2 respectively; p < 0.0001). Women with invasive disease were more likely to experience weight loss or gain, general malaise, chest/respiratory pain, abdominal swelling and bowel symptoms than women with benign ovarian tumors, however the symptom pattern for early- and late-stage invasive ovarian cancer could not be clearly differentiated. There was no suggestion that women with advanced stage disease had delayed longer before presenting to their doctor. The most common reasons given for not telling their doctor about specific symptoms were the woman's perception that the symptom was not serious enough, it was mild or intermittent, or was related to normal physical changes associated with age or menopause.

Conclusions: We found only marginal differences in the symptom patterns of early and advanced stage invasive cancer. Delay in presentation was not associated with more advanced disease suggesting that earlier diagnosis may not increase the proportion of cancers diagnosed at an early stage.

Ovarian neoplasm; Signs and symptoms; Diagnosis

[1] AIHW ＆AACR: "Cancer in Australia 2001". Australian Institute of Health & Welfare, Canberra, AIHW Cat No. CAN 23, 2004, 141.

[2] Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A. et al.: "Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment". J. Natl. Cancer Inst., 2005, 97, 1407.

[3] Ahmed N., Oliva K.T., Barker G., Hoffmann P., Reeve S., Smith I.A. et al.: "Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer". Proteomics, 2005, 5, 4625.

[4] Mor G., Visintin I., Lai Y., Zhao H., Schwartz P., Rutherford T. et al.: "Serum protein markers for early detection of ovarian cancer". Proc. Natl. Acad. Sci USA, 2005, 102, 7677.

[5] Boyce E.A., Kohn E.C.: "Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets". Int. J. Gynecol. Cancer, 2005, 15 (suppl. 3), 266.

[6] Jacobs I.J., Menon U.: "Progress and challenges in screening for early detection of ovarian cancer". Mal. Cell Proteomics, 2004, 3, 355.

[7] "NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer". JAMA, 1995, 273, 491.

[8] Goff B.A., Mandel L.S., Melancon C.H., Muntz H.G.: "Frequency of symptoms of ovarian cancer in women presenting to primary care clinics". JAMA, 2004, 291, 2705.

[9] Bankhead C.R., Kehoe S.T., Austoker J.: "Symptoms associated with diagnosis of ovarian cancer: a systematic review". Br. J. Obstet. Gynaecol., 2005, 112, 857.

[10]Vine MF, Calingaert B, Berchuck A, Schildkraut JM: "Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls". Gynecol.O neal.,2 003,9 0,7 5.

[11] Chan Y.M., Ng T.Y., Lee P.W., Ngan H.Y., Wong L.C.: "Symptoms, coping strategies, and timing of presentations in patients with newly diagnosed ovarian cancer". Gynecol. Oneal., 2003, 90, 651.

[12] Webb P.M., Purdie D.M., Grover S., Jordan S., Dick M.L., Green A.C.: "Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer". Gynecol. Oneal., 2004, 92, 232.

[13] Sonnendecker E.W.: "Cancer of the ovary. The Johannesburg Hospital experience". S. Afr. Med. J., 1988, 73, 713.

[14] Fitch M., Deane K., Howell D., Gray R.E.: "Women's experiences with ovarian cancer: reflections on being diagnosed". Can Oneal. Nurs. J., 2002, 12, 152.

[15] Koldjeski D., Kirkpatrick M.K., Swanson M., Everett L., Brown S.: "Ovarian cancer: early symptom patterns". Oneal. Nurs. Forum, 2003, 30, 927.

[16] Wikborn C., Pettersson F., Moberg P.J.: "Delay in diagnosis of epithelial ovarian cancer". Int. J. Gynaecol.O bstet.,1 996,5 2,2 63.

[17] Yawn B.P., Barrette B.A., Wollan P.C.: "Ovarian cancer: the neglected diagnosis". Mayo Clin. Proc., 2004, 79, 1277.

[18] Goff B.A., Mandel L., Muntz H.G., Melancon C.H.: "Ovarian carcinoma diagnosis". Cancer, 2000, 89, 2068.

[19] Flam F., Einhorn N., Sjovall K.: "Symptomatology of ovarian cancer". Eur. J. Obstet. Gynecol. Reprod. Biol., 1988, 27, 53.

[20] Paulsen T., Kaern J., Kjaerheim K., Trope C., Tretli S.: "Symptoms and referral of women with epithelial ovarian tumors". Int. J. Gynaecol. Obstet., 2005, 88, 31.

[21] Laurvick C.L., Semmens J.B.: "Trends and outcomes for women diagnosed with ovarian cancer in Australia". Aust. Fam. Physician, 2002,31, 1005.

[22] O'Malley C.D., Cress R.D., Campleman S.L., Leiserowitz G.S.: "Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study". Gynecol. Oneal., 2003, 91, 608.

[23] Friedman G.D., Skilling J.S., Udaltsova N.V., Smith L.H.: "Early symptoms of ovarian cancer: a case-control study without recall bias". Fam. Pract., 2005, 22, 548.

[24] Vine M.F., Ness R.B., Calingaert B., Schildkraut J.M., Berchuck A.: "Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor". Gynecol. Oneal., 2001, 83, 466.

[25] Attanucci C.A., Ball H.G., Zweizig S.L., Chen A.H: "Differences in symptoms between patients with benign and malignant ovarian neoplasms". Am. J. Obstet. Gynecol., 2004, 190, 1435.

[26] Smith L.H., Morris C.R., Yasmeen S., Parikh-Patel A., Cress R.D., Romano P.S.: "Ovarian cancer: Can we make the clinical diagnosis earlier?". Cancer, 2005, 104, 1398.

[27] Kirwan J.M., Tincello D.G., Herod J.J., Frost 0., Kingston R.E.: "Effect of delays in primary care referral on survival of women with epithelial ovarian cancer: retrospective audit". Br. Med. J., 2002,3 24,1 48.

[28] Eltabbakh G.H., Yadav P.R., Morgan A.: "Clinical picture of women with early stage ovarian cancer". Gynecol. Oneal, 1999, 75,476.

[29] Kaern J., Aghmesheh M., Nesland J.M., Danielsen H.E., Sandstad B., Friedlander M. et al.: "Prognostic factors in ovarian carcinoma Stage III patients. Can biomarkers improve the prediction of shortand long-term survivors?". Int. J. Gynecol. Cancer , 2005, 15, 1014.

[30] Porta M., Malats N., Belloc J., Gallen M., Fernandez E.: "Do we believe what patients say about their neoplastic symptoms? An analysis of factors that influence the interviewer's judgement". Eur. J. Epidemiol., 1996, 12, 553.

[31] McGowan L.: "Ovarian cancer after hysterectomy". Obstet. Gynecol., 1987, 69, 386.

[32] Sightler S.E., Boike G.M., Estape R.E., Averette H.E.: "Ovarian cancer in women with prior hysterectomy: a 14-year experience at the University of Miami”.Obstet. Gynecol., 1991, 78, 681.

[33] Singer G., Oldt R. 3'', Cohen Y., Wang B.G., Sidransky D., Kurman R.J. et al.: "Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma". J. Natl. Cancer Inst., 2003, 95, 484.

[34] Jordan S., Green A., Webb P.: "Benign epithelial ovarian tumours - cancer precursors or markers for ovarian cancer risk?". Cancer Causes Control, 2006, 17, 623.

[35] Griffiths C.T.: "Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma". Natl. Cancer Inst. Monogr., 1975, 42, 101.